Ferdinando Riccardi

2.8k total citations
77 papers, 875 citations indexed

About

Ferdinando Riccardi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Ferdinando Riccardi has authored 77 papers receiving a total of 875 indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Oncology, 33 papers in Pulmonary and Respiratory Medicine and 21 papers in Epidemiology. Recurrent topics in Ferdinando Riccardi's work include Lung Cancer Research Studies (25 papers), Neuroendocrine Tumor Research Advances (20 papers) and Cancer Treatment and Pharmacology (18 papers). Ferdinando Riccardi is often cited by papers focused on Lung Cancer Research Studies (25 papers), Neuroendocrine Tumor Research Advances (20 papers) and Cancer Treatment and Pharmacology (18 papers). Ferdinando Riccardi collaborates with scholars based in Italy, United States and Malaysia. Ferdinando Riccardi's co-authors include Giacomo Cartenì, Saverio Cinieri, Vittorio Gebbia, Francesca Ambrosio, Andrea Ardizzoni, Luca Boni, Claudio Dazzi, Marcello Tiseo, Generoso Uomo and Francesca Zanelli and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Ferdinando Riccardi

73 papers receiving 860 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ferdinando Riccardi Italy 18 602 296 283 190 122 77 875
Ana Custodio Spain 21 705 1.2× 306 1.0× 334 1.2× 301 1.6× 175 1.4× 75 1.2k
Yangsoon Park South Korea 20 475 0.8× 390 1.3× 244 0.9× 279 1.5× 159 1.3× 59 1.2k
Teresa Alonso‐Gordoa Spain 19 619 1.0× 343 1.2× 333 1.2× 366 1.9× 239 2.0× 82 1.2k
Raffaele Costanzo Italy 16 563 0.9× 368 1.2× 194 0.7× 277 1.5× 147 1.2× 53 899
Hiroki Ueda Japan 16 653 1.1× 307 1.0× 125 0.4× 116 0.6× 112 0.9× 58 916
Cristina Ghiotto Italy 16 362 0.6× 179 0.6× 175 0.6× 101 0.5× 234 1.9× 48 937
Javier Molina‐Cerrillo Spain 17 384 0.6× 303 1.0× 137 0.5× 342 1.8× 249 2.0× 66 967
Venessa Tsang Australia 21 600 1.0× 143 0.5× 322 1.1× 211 1.1× 92 0.8× 48 1.1k
Claudia Sandomenico Italy 18 562 0.9× 366 1.2× 132 0.5× 404 2.1× 124 1.0× 52 987

Countries citing papers authored by Ferdinando Riccardi

Since Specialization
Citations

This map shows the geographic impact of Ferdinando Riccardi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ferdinando Riccardi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ferdinando Riccardi more than expected).

Fields of papers citing papers by Ferdinando Riccardi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ferdinando Riccardi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ferdinando Riccardi. The network helps show where Ferdinando Riccardi may publish in the future.

Co-authorship network of co-authors of Ferdinando Riccardi

This figure shows the co-authorship network connecting the top 25 collaborators of Ferdinando Riccardi. A scholar is included among the top collaborators of Ferdinando Riccardi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ferdinando Riccardi. Ferdinando Riccardi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Blondeaux, Eva, Claudia Bighin, Stefania Russo, et al.. (2024). Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer. npj Breast Cancer. 10(1). 105–105. 1 indexed citations
4.
Maïo, Massimo Di, Claudia Bighin, Francesco Schettini, et al.. (2023). Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study. The Breast. 72. 103583–103583. 5 indexed citations
5.
Faiella, A., et al.. (2022). The Emerging Role of c-Met in Carcinogenesis and Clinical Implications as a Possible Therapeutic Target. Journal of Oncology. 2022. 1–12. 39 indexed citations
6.
7.
Vitale, Maria Giuseppa, Anna Crispo, Francesco Habetswallner, et al.. (2022). Survival analyses of the ZeOxaNMulti trial: Follow-up randomized, double-blinded, placebo-controlled trial of oral PMA-zeolite to prevent chemotherapy-induced side effects, especially peripheral neuropathy. Frontiers in Pharmacology. 13. 874028–874028. 1 indexed citations
8.
Romano, Francesco Jacopo, Francesca Ambrosio, Vito Longo, et al.. (2022). Neutrophil-to-Lymphocyte Ratio Is a Major Prognostic Factor in Non-small Cell Lung Carcinoma Patients Undergoing First Line Immunotherapy With Pembrolizumab. Cancer Diagnosis & Prognosis. 3(1). 44–52. 16 indexed citations
9.
Vitale, Maria Giuseppa, Anna Crispo, Francesco Habetswallner, et al.. (2020). ZeOxaNMulti Trial: A Randomized, Double-Blinded, Placebo-Controlled Trial of Oral PMA-Zeolite to Prevent Chemotherapy-Induced Side Effects, in Particular, Peripheral Neuropathy. Molecules. 25(10). 2297–2297. 11 indexed citations
10.
Sciammarella, Concetta, Amalia Luce, Ferdinando Riccardi, et al.. (2020). Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus. Frontiers in Oncology. 10. 1047–1047. 13 indexed citations
11.
Panzuto, Francesco, Sara Pusceddu, Antongiulio Faggiano, et al.. (2019). Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations. Pancreatology. 19(8). 1067–1073. 18 indexed citations
12.
Placido, Sabino De, Mario Giuliano, Francesco Schettini, et al.. (2018). Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. The Breast. 38. 86–91. 20 indexed citations
13.
Malapelle, Umberto, Simona Vatrano, Stefania Russo, et al.. (2015). EGFR mutant allelic-specific imbalance assessment in routine samples of non-small cell lung cancer. Journal of Clinical Pathology. 68(9). 739–741. 6 indexed citations
14.
15.
Riccardi, Ferdinando, et al.. (2014). Anorexia–cachexia syndrome in pancreatic cancer: Recent advances and new pharmacological approach. Advances in Medical Sciences. 59(1). 1–6. 30 indexed citations
16.
Campiglio, Manuela, Rosaria Bufalino, Elisa Ferri, et al.. (2013). Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study. Breast Cancer Research and Treatment. 141(1). 101–110. 20 indexed citations
17.
Clavarezza, Matteo, Giorgio Mustacchi, Andrea Casadei‐Gardini, et al.. (2012). Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study. BMC Cancer. 12(1). 216–216. 6 indexed citations
18.
Grossi, Francesco, Filippo de Marinis, Vittorio Gebbia, et al.. (2011). A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 69(2). 369–375. 3 indexed citations
19.
20.
Lorusso, Vito, Arcangelo Pagliarulo, Francesco Paolo Selvaggi, et al.. (1996). Treatment of Advanced Urothelial Carcinoma with M-VECA (Methotrexate, Vinblastine, Epirubicin and Carboplatin). Journal of Chemotherapy. 8(2). 154–158. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ana Custodio Breakdown of academic impact, for papers by Yangsoon Park Breakdown of academic impact, for papers by Teresa Alonso‐Gordoa Breakdown of academic impact, for papers by Raffaele Costanzo Breakdown of academic impact, for papers by Hiroki Ueda Breakdown of academic impact, for papers by Cristina Ghiotto Breakdown of academic impact, for papers by Javier Molina‐Cerrillo Breakdown of academic impact, for papers by Venessa Tsang Breakdown of academic impact, for papers by Claudia Sandomenico
Rankless by CCL
2026